These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7513334)

  • 1. Successful control of intractable nausea and vomiting requiring combined ondansetron and haloperidol in a patient with advanced cancer.
    Cole RM; Robinson F; Harvey L; Trethowan K; Murdoch V
    J Pain Symptom Manage; 1994 Jan; 9(1):48-50. PubMed ID: 7513334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ondansetron in nausea and vomiting induced by spinal morphine.
    Mercadante S; Sapio M; Serretta R
    J Pain Symptom Manage; 1998 Oct; 16(4):259-62. PubMed ID: 9803054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ondansetron, an antagonist of 5-HT3 receptors, in the treatment of antineoplastic drug-induced nausea and vomiting in children.
    Matera MG; Di Tullio M; Lucarelli C; Casale F; Calabria C; Lampa E; Indolfi P; Rossi F
    J Med; 1993; 24(2-3):161-70. PubMed ID: 7691978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis.
    Simino GP; Marra LP; Andrade EI; Acúrcio Fde A; Reis IA; De Araújo VE; Cherchiglia ML
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1183-94. PubMed ID: 27180992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ondansetron in the treatment of nausea and vomiting. Introduction.
    Marschner N
    Anticancer Drugs; 1993 Dec; 4 Suppl 2():3-7. PubMed ID: 8136513
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of postoperative nausea and vomiting with ondansetron in patients administered anti-neoplastic agents].
    Morimoto Y; Nakamura M; Tamura T; Kunii T; Shimizu K; Miyauchi Y
    Masui; 1996 Sep; 45(9):1096-9. PubMed ID: 8905945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An overview of ondansetron for chemotherapy-induced nausea and emesis.
    San Angel F
    J Intraven Nurs; 1993; 16(2):84-9. PubMed ID: 8478782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of haloperidol, dexamethasone, and ondansetron reduces nausea and pain intensity and morphine consumption after laparoscopic sleeve gastrectomy.
    Benevides ML; Oliveira Sde S; Aguilar-Nascimento JE
    Braz J Anesthesiol; 2013; 63(5):404-9. PubMed ID: 24263044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults.
    Billio A; Morello E; Clarke MJ
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006272. PubMed ID: 20091591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oral ondansetron, a selective antagonist of 5-HT3 receptors, in the treatment of nausea and vomiting associated with cyclophosphamide-based chemotherapies. Ondansetron Study Group.
    Cubeddu LX; Pendergrass K; Ryan T; York M; Burton G; Meshad M; Galvin D; Ciociola AA
    Am J Clin Oncol; 1994 Apr; 17(2):137-46. PubMed ID: 8141105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haloperidol versus ondansetron for prophylaxis of postoperative nausea and vomiting.
    Rosow CE; Haspel KL; Smith SE; Grecu L; Bittner EA
    Anesth Analg; 2008 May; 106(5):1407-9, table of contents. PubMed ID: 18420852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ondansetron in intractable nausea and vomiting.
    Nicholson S; Evans C; Mansi J
    Lancet; 1992 Feb; 339(8791):490. PubMed ID: 1346838
    [No Abstract]   [Full Text] [Related]  

  • 13. Ondansetron: perioperative use of a serotonin receptor antagonist for the prevention and treatment of nausea and vomiting.
    Early TE; Charbonneau J; McKnight G; Jenkins P
    J Post Anesth Nurs; 1995 Dec; 10(6):320-3. PubMed ID: 8632370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ondansetron. An update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting.
    Markham A; Sorkin EM
    Drugs; 1993 Jun; 45(6):931-952. PubMed ID: 7691500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron, clinical development for postoperative nausea and vomiting: current studies and future directions.
    Joslyn AF
    Anaesthesia; 1994 Jan; 49 Suppl():34-7. PubMed ID: 7907459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts.
    McLean SL; Blenkinsopp A; Bennett MI
    J Pain Palliat Care Pharmacother; 2013 Jun; 27(2):132-5. PubMed ID: 23627663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ondansetron (GR 38032F), a competitive 5-HT3 receptor antagonist as an antiemetic in cytostatic drug-induced nausea and vomiting. An open, substance-oriented phase II/III study].
    Serve H; Perker M; Ertl A; Reichold M; Fink U; Berdel WE
    Onkologie; 1990 Oct; 13(5):369-74. PubMed ID: 2150552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ondansetron for treating nausea and vomiting in the poisoned patient.
    Reed MD; Marx CM
    Ann Pharmacother; 1994 Mar; 28(3):331-3. PubMed ID: 8193420
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recent improvements in antiemetic therapy].
    Roila F; Palladino MA; Ciccarese G; Basurto C
    Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [An outline of 5-HT3 receptor antagonists (2)--In clinical applications].
    Tsukagoshi S; Ohta J; Taguchi T
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2276-81. PubMed ID: 8259839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.